Wildmicrobes uses synthetic biology to discover and engineer thousands of untapped microbial species from wild environments, creating production strains that synthesize high‑performance ingredients such as emulsifiers, vitamins, and industrial chemicals. Their high‑throughput genomics and bioinformatics pipeline identifies native biosynthetic pathways that reduce raw‑material costs and enable novel molecular functionalities, allowing ingredient manufacturers and specialty chemical producers to replace conventional inputs with renewable, bio‑derived alternatives.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional biomanufacturing relies on a narrow set of well‑characterized microbes, which often lack the metabolic capabilities needed for high‑performance, sustainable ingredient production. This limits cost efficiency, product diversity, and the ability to replace petro‑based chemicals with bio‑derived alternatives.
Solution
Wildmicrobes applies synthetic biology to unlock the metabolic potential of thousands of previously untapped microbial species sourced from diverse wild environments. By isolating and engineering these “wild” microbes, the company creates production strains that can synthesize emulsifiers, cleansers, vitamins, supplements, and industrial chemicals more efficiently than traditional hosts. Their discovery engine screens millions of candidates to identify traits that reduce raw‑material costs and enable novel molecular functionalities. Engineered strains are then scaled in bioprocesses that deliver renewable, high‑purity ingredients to partners seeking greener product lines.
Target Audience
Primary customers are ingredient manufacturers, consumer‑goods companies, and specialty chemical producers looking to replace conventional inputs with bio‑derived, high‑performance alternatives.
Features
- Systematic sampling of wild biomes to access an estimated trillion microbial species for bioprospecting
- High‑throughput genomics and bioinformatics pipeline to identify promising biosynthetic pathways
- Synthetic biology platform that refactors native genes into robust, industrial‑grade production strains
- Tailored strain optimization for cost‑effective fermentation of target molecules
- Ability to generate a broad portfolio of ingredients, from surfactants to nutraceuticals, without relying on existing commercial microbes
- Scalable manufacturing workflow that integrates engineered microbes into existing bioprocess infrastructure